Quarterly Activities/Appendix 4C Cash Flow Report

• Continued progress in Pivotal Trial for FDA clearance, with 8 hospitals now recruiting
• Growing international clinical awareness, featured at NABI Conference and preparing publication
• Reporting expected on pre-hospital feasibility studies for First Responder device

EMVision Medical Devices continued to make solid progress in its Pivotal (Validation) Trial designed to support FDA De Novo clearance, with eight leading hospitals now actively recruiting and ramping up. Initiatives including broader clinical team engagement and additional after-hours coverage are supporting building recruitment momentum, while no device-related adverse events have been reported. International clinical awareness is also growing, with EMVision's technology featured at NABI Conference Texas Medical Centre 2026 and an early clinical experience paper from the pivotal study prepared for publication by a leading US academic centre. EMVision also reported expected reporting this quarter across multiple pre-hospital feasibility and usability studies for the First Responder device including aeromedical and mobile stroke unit studies. The grant-funded emuâ„¢ Regional Benefits Study is progressing through preparations ahead of launch in 2H CY2026, with the second grant payment of $0.4 million received during the quarter. The company received a $3.8m R&D tax refund in relation to eligible R&D activities undertaken for FY25 and has $18.4m in cash reserves as at 31 March 2026, with further non-dilutive funding available under current grant programs ($6.6m).

EMVision is well-funded with cash reserves of $18.4m as at 31 March 2026 and further non-dilutive funding available under current grant programs ($6.6m), providing a strong runway to execute on commercialisation milestones.